Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier

Biomaterials

Volumn 35, Issue 38, 2014, Pages 10058-10069

  Chen, Yijie ^a,b   Gu, Hongchen ^a,b   Zhang, Ding Sheng Zi ^b   Li, Fan ^a,b   Liu, Tengyuan ^b   Xia, Weiliang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Lung cancer therapy; Mesoporous silica nanoparticles; Metastasis; SiRNA; Systemic delivery; VEGF

Indexed keywords

BIOCOMPATIBILITY; BIOLOGICAL ORGANS; CYTOLOGY; MESOPOROUS MATERIALS; NANOMAGNETICS; NANOPARTICLES; ONCOLOGY; PATHOLOGY; RNA; SILICA; SILICA NANOPARTICLES; TUMORS;

LUNG CANCER THERAPY; MESOPOROUS SILICA NANOPARTICLES; METASTASIS; SIRNA; SYSTEMIC DELIVERIES; VEGF;

DISEASES;

MAGNETIC MESOPOROUS SILICA NANOPARTICLE; NANOCARRIER; POLYETHYLENEIMINE; SILICON DIOXIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; NANOCAPSULE; VASCULOTROPIN A;

ARTICLE; BIOCOMPATIBILITY; BIOSAFETY; CANCER GROWTH; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; METASTASIS; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DIFFUSION; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; MOUSE; NANOPORE; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; POROSITY; PROCEDURES; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DIFFUSION; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; NANOCAPSULES; NANOPORES; NEOPLASMS, EXPERIMENTAL; POROSITY; RNA, SMALL INTERFERING; TRANSFECTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908093790     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.09.003     Document Type: Article

References (40)

1. Siegel R., Naishadham D., Jemal A. Cancer Stat 2013, 63:11-30.
2. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann Oncol 2013, 24:792-800.
3. Carney D.N. Lung cancer-time to move on from chemotherapy. NEngl J Med 2002, 346:126-129.
4. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
5. Hannon G.J., Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 2004, 431:371-378.
6. Miele E., Spinelli G.P., Miele E., Di Fabrizio E., Ferretti E., Tomao S., et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomed 2012, 7:3637-3657.
7. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. Invivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007, 13:372-377.
8. Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., et al. Therapeutic EphA2 gene targeting invivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005, 65:6910-6918.
9. Xue H.-Y., Wong H.-L. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011, 5:7034-7047.
10. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
11. Chen C.-J., Wang J.-C., Zhao E.-Y., Gao L.-Y., Feng Q., Liu X.-Y., et al. Self-assembly cationic nanoparticles based on cholesterol-grafted bioreducible poly(amidoamine) for siRNA delivery. Biomaterials 2013, 34:5303-5316.
12. Gary D.J., Puri N., Won Y.-Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. JControl Release 2007, 121:64-73.
13. Shim G., Han S.-E., Yu Y.-H., Lee S., Lee H.Y., Kim K., et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. JControl Release 2011, 155:60-66.
14. Meng H., Mai W.X., Zhang H., Xue M., Xia T., Lin S., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer invitro and invivo. ACS Nano 2013, 7:994-1005.
15. Chen Y., Chen H., Shi J. Invivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv Mater 2013, 25:3144-3176.
16. Hartono S.B., Gu W., Kleitz F., Liu J., He L., Middelberg A.P.J., et al. Poly-l-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery. ACS Nano 2012, 6:2104-2117.
17. Lin D., Cheng Q., Jiang Q., Huang Y., Yang Z., Han S., et al. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery invitro and invivo. Nanoscale 2013, 5:4291-4301.
18. Li X., Chen Y., Wang M., Ma Y., Xia W., Gu H. Amesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013, 34:1391-1401.
19. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
20. Ma X., Zhao Y., Ng K.W., Zhao Y. Integrated hollow mesoporous silica nanoparticles for target Drug/siRNA co-delivery. Chemistry 2013, 15593-15603.
21. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
22. Folkman J. What is the evidence that tumors are angiogenesis dependent?. JNatl Cancer Inst 1990, 82:4-6.
23. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
24. Ohta Y., Endo Y., Tanaka M., Shimizu J., Oda M., Hayashi Y., et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996, 2:1411-1416.
25. Welti Jonathan, Loges Sonja, Stefanie Dimmeler P.C. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. JClin Invest 2013, 123:3190-3200.
26. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. Asmall interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-3370.
27. Li X., Xie Q.R., Zhang J., Xia W., Gu H. The packaging of siRNA within the mesoporous structure of silica nanoparticles. Biomaterials 2011, 32:9546-9556.
28. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., Szoka F.C. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry 1997, 36:3008-3017.
29. Yang X., Du J., Dou S., Mao C., Long H., Wang J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. ACS Nano 2012, 6:771-781.
30. Benezra M., Penate-Medina O., Zanzonico P.B., Schaer D., Ow H., Burns A., et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. JClin Invest 2011, 121:2768-2780.
31. Rosenholm J.M., Mamaeva V., Sahlgren C., Lindén M. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. Nanomedicine (Lond) 2012, 7:111-120.
32. Maeda H., Fang J., Inutsuka T., Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003, 3:319-328.
33. Whitehead K. a, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
34. He Q., Zhang Z., Gao F., Li Y., Shi J. Invivo biodistribution and urinary excretion of mesoporous silica nanoparticles effects of particle size and PEGylation.pdf. Small 2011, 7:271-280.
35. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W.Y. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2:711-719.
36. Niki T., Iba S., Tokunou M., Adenocarcinoma L. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 2000, 6:2431-2439.
37. Trang P., Wiggins J.F., Daige C.L., Cho C., Omotola M., Brown D., et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011, 19:1116-1122.
38. Donnem T., Andersen S., Al-Shibli K., Al-Saad S., Busund L.-T., Bremnes R.M. Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 2010, 116:5676-5685.
39. Liu Q., Zhang J., Sun W., Xie Q.R., Xia W., Gu H. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. Int J Nanomedicine 2012, 7:999-1013.
40. Lee C.-H., Cheng S.-H., Huang I.-P., Souris J.S., Yang C.-S., Mou C.-Y., et al. Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. Angew Chem Int Ed Engl 2010, 49:8214-8219.